GSK has separated from Haleon - Trends-Tendances sur PC

GSK has separated from Haleon – Trends-Tendances sur PC

Last week, Haleon debuted on the London Stock Exchange for an overall successful IPO. Haleon is the joint venture owned by GSK (68%) and Pfizer (32%). It arises from the merger of…

Last week, Haleon debuted on the London Stock Exchange for an overall successful IPO. Haleon is the joint venture owned by GSK (68%) and Pfizer (32%). It stems from the merger of the consumer health divisions of the two pharmaceutical groups in 2019. Haleon is a successful business: 23,000 employees, 9.5 billion pounds in turnover and 1.6 billion in profits in 2021. We You will find brands as well known as Sensodyne, Voltaren, Advil, Nicorette or Panadol. Anxious to refocus on the manufacture of innovative vaccines and specialized drugs, GSK wanted to separate from the consumer activities. Moreover, the two groups aim to gradually resell all of their shares. The idea for GSK is to be more agile but also better valued by the financial markets. A wish, among others, of activist funds like Elliott. A time, Unilever had shown interest in a takeover of Haleon but its offer had been rejected.

.

Leave a Comment

Your email address will not be published.